TINAGL1 Human

TINAGL1, also known as Tubulointerstitial Nephritis Antigen-Related Protein, is a glycoprotein that belongs to the peptidase C1 family. The mature human TINAGL1 protein contains several distinct domains, including an SMB (somatomedin B) domain, a vWFC (von Willebrand factor type C) domain, and a nonenzymatic peptidase C1A region . These structural features contribute to its functional versatility.

TINAGL1 is implicated in a variety of biological processes. It is known to play a role in the zonal differentiation of adrenocortical cells, where it is referred to as adrenocortical zonation factor 1 (AZ-1) or lipocalin 7 . Additionally, TINAGL1 has been associated with the regulation of gene expression in adrenocortical cells, particularly in repressing the expression of the CYP11B1 gene .

TINAGL1 has been studied extensively in the context of cancer. It has been proposed to both protect against cancer and contribute to pathological abnormalities in tumors . For instance, in diffuse-type gastric cancer (DGC), TINAGL1 secreted by cancer-associated fibroblasts (CAFs) has been shown to promote tumor progression by inducing the phosphorylation of focal adhesion kinase (FAK) in cancer cells . This interaction enhances the migration and tumorigenesis of DGC cells, making TINAGL1 a potential therapeutic target for this type of cancer.

The recombinant form of TINAGL1 is produced using advanced biotechnological methods to ensure high purity and activity. This form is particularly useful in research and therapeutic applications, as it allows for the detailed study of TINAGL1’s functions and interactions in a controlled environment. Recombinant TINAGL1 is utilized in various assays and experimental setups to investigate its role in different biological processes and diseases .